Compliance with clinical guidelines and adherence to antiretroviral therapy among patients living with HIV

References

• Centers for Disease Control and Prevention. HIV in the United States: at a glance. Atlanta, GA, CDCP; 2017. Available at: https://www.cdc.gov/hiv/statistics/overview/ataglance.html [Last accessed 19 June 2017]
   Google Scholar
• Centers for Disease Control and Prevention. HIV surveillance report. Atlanta, GA, CDCP; 2016. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf [Last accessed 19 June 2017]
   Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013;8:e81355
   PubMed Web of Science ®Google Scholar
• US Department of Health & Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC, US DoHHS; 2016. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0 [Last accessed 3 February 2016]
   Google Scholar
• McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis 2011;52:493-506
   PubMed Web of Science ®Google Scholar
• Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med 2010;152:18-25
   PubMed Web of Science ®Google Scholar
• Gardner EM, Maravi ME, Rietmeijer C, et al. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy 2008;6(2–3):145-55
   PubMedGoogle Scholar
• Cocohoba J, Wang QJ, Cox C, et al. Consistency of initial antiretroviral therapy with HIV treatment guidelines in a US cohort of HIV-infected women. J Acquir Immune Defic Syndr 2008;47:377-83
   PubMed Web of Science ®Google Scholar
• Cooke CE, Lee HY, Xing S. Adherence to antiretroviral therapy in managed care members in the United States: a retrospective claims analysis. J Manag Care Pharm 2014;20:86-92
   PubMed Web of Science ®Google Scholar
• Johnston SS, Juday T, Farr AM, et al. Comparison between guideline-preferred and nonpreferred first-line HIV antiretroviral therapy. Am J Manag Care 2014;20:448-55
   PubMed Web of Science ®Google Scholar
• Ghani AC, Donnelly CA, Anderson RM. Patterns of antiretroviral use in the United States of America: analysis of three observational databases. HIV Med 2003;4:24-32
   PubMedGoogle Scholar
• Holodniy M, Hornberger J, Rapoport D, et al. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naive HIV-1-infected US veterans (1992–2004). J Acquir Immune Defic Syndr 2007;44:20-9
   PubMed Web of Science ®Google Scholar
• Cocohoba JM, Althoff KN, Godfrey R, et al. Influence of gender on receipt of guideline-based antiretroviral therapy in the era of HAART. AIDS Care 2012;24:20-9
   PubMed Web of Science ®Google Scholar
• Hirsch JD, Gonzales M, Rosenquist A, et al. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm 2011;17:213-23
   PubMed Web of Science ®Google Scholar
• Abara WE, Adekeye OA, Xu J, et al. Adherence to combination antiretroviral treatment and clinical outcomes in a Medicaid sample of older HIV-infected adults. AIDS Care 2017;29:441-8
   PubMed Web of Science ®Google Scholar
• Murphy P, Cocohoba J, Tang A, et al. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. AIDS Patient Care STDS 2012;26:526-31
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
   PubMed Web of Science ®Google Scholar
• HCUP CCS [computer program]. Rockville, MD: Agency for Healthcare Research and Quality; 2015. Available at: https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
   Google Scholar
• US Department of Health & Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Archived adult and adolescent guidelines. Washington, DC, US DoHHS; 2016. Available at: https://aidsinfo.nih.gov/guidelines/archive/adult-and-adolescent-guidelines/ [Last accessed 12 April 2017]
   Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74; discussion 575–77
   PubMed Web of Science ®Google Scholar
• Nau DP. Proportion of days covered as a preferred method of measuring medication adherence. Alexandria, VA, Quality Alliance; 2012. Available at: http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf [Last accessed 19 May 2017]
   Google Scholar
• US Department of Health & Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Archived adult and adolescent guidelines. Washington, DC, US DoHHS; 2014. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL003392.pdf [Last accessed 7 August 2018]
   Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013;13:927-35
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013;369:1807-18
   PubMed Web of Science ®Google Scholar
• Feinberg J, Clotet B, Khuong-Josses MA. Once-daily dolutegravir (DTG) is superior to darunavir/ritonavir (DRV/r) in antiretroviral-naïve adults: 48 week results from FLAMINGO (ING114915). Presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO; 10-13 September 2013
   Google Scholar
• Clumeck N, Molina J, Henry K, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 144 in treatment-naive HIV-1 infected patients. Presented at the 14th European AIDS Conference. Brussels, Belgium; 16-19 October 2013
   Google Scholar
• Mujeebuddin S, Mao J, Bengtson LGS, et al. HIV treatment guidelines and medication initiation patterns in treatment naive adults, 2008–2016. Value Health 2018;18:S160
   Google Scholar
• King WD, Minor P, Ramirez Kitchen C, et al. Racial, gender and geographic disparities of antiretroviral treatment among US Medicaid enrolees in 1998. J Epidemiol Community Health 2008;62:798-803
   PubMed Web of Science ®Google Scholar
• Fleishman JA, Yehia BR, Moore RD, et al. Disparities in receipt of antiretroviral therapy among HIV-infected adults (2002–2008). Med Care 2012;50:419-27
   PubMed Web of Science ®Google Scholar
• Wandeler G, Keiser O, Hirschel B, et al. A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS One 2011;6:e27903
   PubMed Web of Science ®Google Scholar
• Loutfy MR, Sherr L, Sonnenberg-Schwan U, et al. Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc 2013;16:18509
   PubMed Web of Science ®Google Scholar
• Monforte A, Anderson J, Olczak A. What do we know about antiretroviral treatment of HIV in women? Antivir Ther 2013;18(Suppl 2):27-34
   PubMedGoogle Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30
   PubMed Web of Science ®Google Scholar
• Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008;61:769-73
   PubMed Web of Science ®Google Scholar
• Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-41
   PubMed Web of Science ®Google Scholar
• Viswanathan S, Detels R, Mehta SH, et al. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav 2015;19:601-11
   PubMed Web of Science ®Google Scholar
• Sutton SS, Magagnoli J, Hardin JW. Odds of viral suppression by single-tablet regimens, multiple-tablet regimens, and adherence level in HIV/AIDS patients receiving antiretroviral therapy. Pharmacotherapy 2017;37:204-13
   PubMed Web of Science ®Google Scholar
• Cambiano V, Lampe FC, Rodger AJ, et al. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. HIV Med 2010;11:216-24
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007;146:564-73
   PubMed Web of Science ®Google Scholar
• King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 2005;191:2046-52
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials 2007;8:282-92
   PubMed Web of Science ®Google Scholar
• von Wyl V, Klimkait T, Yerly S, et al. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. PLoS One 2013;8:e77691
   PubMed Web of Science ®Google Scholar
• Lafeuille M, Woodruff K, Dunn K, et al. Adherence to antiretrovirals in Medicaid-insured patients living with human immunodeficiency virus. J Manag Care Pharm 2017;23(Suppl 3-a):S26
   Google Scholar
• Gonzalez-Serna A, Chan K, Yip B, et al. Temporal trends in the discontinuation of first-line antiretroviral therapy. J Antimicrob Chemother 2014;69:2202-9
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Mattson CL, Scheer S, et al. Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States. J Acquir Immune Defic Syndr 2014;66:80-9
   PubMed Web of Science ®Google Scholar
• Capetti A, Cossu MV, Rizzardini G. Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance. Expert Opin Pharmacother 2015;16:2689-702
   PubMed Web of Science ®Google Scholar